Townsend & Associates’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Townsend & Associates's BMY Position: Q2 2026 in Review
Townsend & Associates reduced its Bristol-Myers Squibb (BMY) stake by 1.2% in Q2 2026, selling an estimated $31.4K and leaving 45,898 shares worth $2.76M. The position accounts for 0.24% of the portfolio, ranked #52.
Townsend & Associates first reported a position in BMY in Q2 2022 and has held it in 17 quarters since. The position peaked at $2.94M in Q1 2023. 878 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Townsend & Associates held 45,898 shares of Bristol-Myers Squibb worth $2.76M as of Q2 2026.
- Townsend & Associates sold 547 Bristol-Myers Squibb shares in Q2 2026, an estimated $31.4K.
- Bristol-Myers Squibb made up 0.24% of Townsend & Associates's portfolio in Q2 2026, its #52 holding.
- Townsend & Associates first reported a position in Bristol-Myers Squibb in Q2 2022 and has held it in 17 quarters since.
- Townsend & Associates's Bristol-Myers Squibb position peaked at $2.94M in Q1 2023.
- 878 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Townsend & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.